Vimarsana
Biggest News Aggregation in the World

Page 2 - Controlled Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Controlled Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Controlled Trial Today - Breaking & Trending Today

Advancing Lupus Care: The Changing Landscape of Treatment - Vimarsana News

Advancing Lupus Care: The Changing Landscape of Treatment

The progression toward more targeted, disease-modifying options for the historically difficult rheumatic disease made more headway in 2023.

Home Remedies for High Blood Pressure / Hypertension - Vimarsana News

Home Remedies for High Blood Pressure / Hypertension

Home remedies offer you herbal and natural methods to treat high blood pressure or hypertension. Follow these simple and natural remedies to lower or control high blood pressure.

Eculizumab Biosimilar Comparable for Complement-Inhibitor Naive Patients with Paroxysmal Nocturnal Hemoglobinuria - Vimarsana News

Eculizumab Biosimilar Comparable for Complement-Inhibitor Naive Patients with Paroxysmal Nocturnal Hemoglobinuria

These results in the subgroup analysis, seen among individuals who were both identified as Asian and non-Asian, align with data published previously in the overall population.

NCCN Announces Funding for Advanced Prostate Cancer Research Projects - Vimarsana News

NCCN Announces Funding for Advanced Prostate Cancer Research Projects

/PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced grants awarded for developing innovative...

Study Supports the Efficacy, Safety of Ravulizumab for Patients with IgA Nephropathy - Vimarsana News

Study Supports the Efficacy, Safety of Ravulizumab for Patients with IgA Nephropathy

The ravulizumab group had a proteinuria reduction of 40.3% while the placebo group had a reduction of 10.9% by week 26, highlighting ravulizumab’s effectiveness in treating patients with IgA Nephropathy.